Featured Research

from universities, journals, and other organizations

Why Past Oral Contraceptive Use Dramatically Lowers Risk Of Ovarian And Uterine Cancers

Date:
October 23, 2008
Source:
Wake Forest University Baptist Medical Center
Summary:
Researchers may be one step closer to understanding why past oral contraceptive use dramatically lowers the risk of ovarian and uterine cancers later in life. Birth control has a long-term effect on hormone exposure.

Researchers at Wake Forest University School of Medicine may be one step closer to understanding why past oral contraceptive use dramatically lowers the risk of ovarian and uterine cancers later in life.

While studying the effect of post-menopausal dietary soy consumption on estrogen metabolism in cynomolgus monkeys, Latanya M. Scott, Ph.D., discovered that monkeys who had been given birth control earlier in life had a reduced amount of estrogen excreted in their urine. The research was done in collaboration with Xia Xu, Ph.D., and Timothy Veenstra, Ph.D. at Science Applications International Corporation-Frederick, Inc., in Frederick, Md., who have developed novel methods for analysis of urinary estrogens.

The discovery was particularly noteworthy because it was found three years after oral contraceptive treatment was stopped, roughly the equivalent of a decade of life in a human.

While researchers have known for many years that past oral contraceptive use significantly lowers the risk of ovarian and uterine cancers later in life, this new observation in monkeys may shed light on the mechanism behind the cancer-protective effect of the treatment. Past oral contraceptive use appears to result in a long-term change in the way the monkeys' bodies process hormones. While researchers don't yet understand the precise mechanism by which hormone levels are being affected, they do know that both the level of estrogen in the blood and the amount of estrogen being excreted in urine are lowered with past oral contraceptive use, which may mean that the oral contraceptive use is somehow leading to a diminished synthesis of estrogen.

"Hormone exposure has long been known to be important in cancer risk," said J. Mark Cline, D.V.M., Ph.D., and senior researcher on the project. "These effects are robust, and we believe this discovery could be translated fairly quickly into a study in women. If our results are confirmed to also occur in women, they could change the way we look at oral contraceptives and cancer risk," added Cline, a professor of pathology and comparative medicine.

With funding from the National Institutes of Health, researchers began with 181 premenopausal cynomolgus monkeys and followed them for seven years in a study designed to look at hormone effects on many aspects of female health.

Half of the monkeys were given a birth control treatment of triphasic estrogen and progestin, marketed by Wyeth Pharmaceuticals as TriphasilTM, for 26 months. At the end of the premenopausal phase of the study, the animals underwent surgery to have their ovaries removed, making them surgically menopausal.

The postmenopausal monkeys were then divided into three dietary intervention groups to evaluate the effects of soy on hormone metabolism.

Urine samples were collected from each monkey during the 35th and 36th months of the postmenopausal phase of the study and frozen for subsequent analysis of metabolite concentrations.

Lab results showed that the premenopausal use of oral contraceptives resulted in significantly lower levels of most estrogen metabolites three years after surgical menopause. Among the most abundant metabolites, percent changes ranged from a 25 percent reduction in E1 to a 50 percent reduction in 2OHE1 with oral contraceptive administration. Postmenopausal dietary isoflavones induced fewer significant effects on postmenopausal estrogen metabolite concentrations.

"The magnitude and persistence of oral contraceptive effect really surprised us," said Cline, a diplomate of the American College of Veterinary Pathologists. "It tells us that there may be a new and potentially strong cancer-protective mechanism at work. This could open new doors of inquiry in the field."

The study appears in this month's issue of Cancer Epidemiology, Biomarkers and Prevention.

All procedures involving the animals were conducted in compliance with state and federal laws, standards of the U.S. Department of Health and Human Services, and guidelines established by the Wake Forest University Animal Care and Use Committee.

In addition to the National Institutes of Health, the study received funding from the National Cancer Institute and National Center for Complementary and Alternative Medicine.

Co-researchers were lead author Latanya M. Scott, Ph.D., Charles E. Wood, D.V.M., Ph.D., Thomas C. Register, Ph.D., Nancy D. Kock, D.V.M., Ph.D., and Janet A. Tooze, Ph.D., all of the Wake Forest University School of Medicine, and Xia Xu and Timothy D. Veenstra, both of Science Applications International Corporation-Frederick, Inc., in Frederick, Md.

Media Relations Contacts: Jessica Guenzel, .edu, (336) 716-3487; Bonnie Davis, .edu, (336) 716-4977; or Shannon Koontz, .edu, (336) 716-4587

Wake Forest University Baptist Medical Center (http://www.wfubmc.edu) is an academic health system comprised of North Carolina Baptist Hospital, Brenner Children's Hospital, Wake Forest University Physicians, and Wake Forest University Health Sciences, which operates the university's School of Medicine and Piedmont Triad Research Park. The system comprises 1,154 acute care, rehabilitation and long-term care beds and has been ranked as one of "America's Best Hospitals" by U.S. News & World Report since 1993. Wake Forest Baptist is ranked 32nd in the nation by America's Top Doctors for the number of its doctors considered best by their peers. The institution ranks in the top third in funding by the National Institutes of Health and fourth in the Southeast in revenues from its licensed intellectual property.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Why Past Oral Contraceptive Use Dramatically Lowers Risk Of Ovarian And Uterine Cancers." ScienceDaily. ScienceDaily, 23 October 2008. <www.sciencedaily.com/releases/2008/10/081020171345.htm>.
Wake Forest University Baptist Medical Center. (2008, October 23). Why Past Oral Contraceptive Use Dramatically Lowers Risk Of Ovarian And Uterine Cancers. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2008/10/081020171345.htm
Wake Forest University Baptist Medical Center. "Why Past Oral Contraceptive Use Dramatically Lowers Risk Of Ovarian And Uterine Cancers." ScienceDaily. www.sciencedaily.com/releases/2008/10/081020171345.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins